Ulrik N.
- Country
- Sweden
- Department
- Oncology
Research Overview
- Evaluation of Sacituzumab Tirumotecan with Carboplatin/Paclitaxel and Pembrolizumab in High-Risk Early-Stage Triple-Negative or HR-Low/HER2-Negative Breast Cancer
- IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment
Data & Insights
Has run more than one trial at 20 of 146 partner sites.
Specializations
Haematological malignancies
Clinical research activity includes a broad focus on leukaemia, lymphoma, and multiple myeloma, with interest in both newly diagnosed and relapsed or refractory disease. The portfolio also extends to myelodysplastic syndromes and related marrow disorders.
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Diffuse large B-cell lymphoma
- Multiple myeloma
- Myelodysplastic syndrome
Therapeutic interest is centred on immunotherapy, targeted treatment, and transplant-related strategies in blood cancers.
Solid tumours and precision oncology
Research involvement spans major solid-tumour areas, especially breast cancer, prostate cancer, colorectal cancer, ovarian cancer, and non-small cell lung cancer. The landscape also includes melanoma, pancreatic cancer, and gastrointestinal malignancies.
- Breast cancer
- Prostate cancer
- Colorectal cancer
- Ovarian cancer
- Non-small cell lung cancer
Key therapeutic domains include biomarker-driven treatment, HER2-directed therapy, and androgen receptor pathway inhibition.
Autoimmune, inflammatory, and rare immune-mediated disease
Clinical interests include rheumatoid arthritis, systemic sclerosis, vasculitis, IgG4-related disease, Crohn’s disease, and ulcerative colitis. The portfolio also covers asthma, chronic rhinosinusitis with nasal polyps, and other inflammatory conditions.
- Rheumatoid arthritis
- Systemic sclerosis
- Vasculitis
- IgG4-related disease
- Inflammatory bowel disease
Therapeutic emphasis is placed on immune modulation, anti-inflammatory treatment, and organ-protective care.
Cardiovascular, renal, and metabolic disease
Research activity includes heart failure, atrial fibrillation, coronary artery disease, stroke prevention, chronic kidney disease, and diabetes mellitus. Additional interests include hyperlipidaemia, amyloidosis, and thrombotic complications.
- Heart failure
- Chronic kidney disease
- Type 1 diabetes
- Type 2 diabetes
- Stroke prevention
The therapeutic focus includes cardiorenal protection, vascular risk reduction, and metabolic disease management.
Neurodegenerative, paediatric, and supportive care conditions
Clinical interests also reach into Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and selected paediatric oncology and haematology settings. The portfolio includes infection-related disorders, critical illness, and other supportive-care domains.
- Alzheimer’s disease
- Parkinson’s disease
- Amyotrophic lateral sclerosis
- Paediatric cancer
- Severe infection
Therapeutic interest extends to neurological disease modification, paediatric treatment optimisation, and infection management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.